This review highlights the potential future clinical indications of ranolazine for arrhythmias (especially atrial fibrillation) and diastolic dysfunction based on its inhibition of the late Na current.
Answers are grounded in this paper and cite their sources.
May support ranolazine investigation in AF and diastolic dysfunction; leaves open randomized confirmation before practice change.
The late Na current is of pathophysiological importance for the heart. Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. Moreover, there are experimental and clinical data about its antiarrhythmic properties. A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation. The purpose of this review article is to discuss possible future clinical indications based on novel experimental and preclinical results and the significance of the available data.
No takes yet. Share an insight, caveat, or question.
Lars S. Maier (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: